# Axicabtagene Ciloleucel Expanded Access Study

> **NCT03153462** · — · APPROVED_FOR_MARKETING · sponsor: **Kite, A Gilead Company**

## Conditions studied

- Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Relapsed/Refractory Primary Mediastinal B Cell Lymphoma
- Relapsed/Refractory Transformed Follicular Lymphoma
- Relapsed/Refractory High-Grade B-Cell Lymphoma

## Interventions

- **BIOLOGICAL:** Axicabtagene Ciloleucel

## Key facts

- **NCT ID:** NCT03153462
- **Lead sponsor:** Kite, A Gilead Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03153462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03153462, "Axicabtagene Ciloleucel Expanded Access Study". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03153462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*